- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Samuel Aparicio, BM, BCh, PhD, FRCPath FRSC
Nan & Lorraine Robertson Chair in Breast Cancer Research
Canada Research Chair in Molecular Oncology
Distinguished Scientist and Head, Department of Molecular Oncology,
BC Cancer, a part of the Provincial Health Services Authority
Professor, Department of Pathology & Laboratory Medicine
Fellow, Royal Society of Canada, Life Science Division
University of British Columbia
Goal: To develop new strategies for personalized therapy for patients with triple negative breast cancer (TNBC).
Impact: Dr. Aparicio has observed at least four distinct patterns in DNA structure of many TNBC tumors—patterns that could predict response to drugs that directly target DNA. Recently, he and his team have furthered their understanding of which patients with TNBC may benefit from a new drug (CX-5461) that is currently in clinical trials.
What’s next: Dr. Aparicio and his team will conduct laboratory studies to test CX-5461 in patient-derived laboratory TNBC tumors. He also plans to test whether the DNA patterns are a sign of the tumor’s tendency to spread to other tissues.
While many patients who have TNBC respond to drugs that damage DNA, new treatments are urgently needed to treat those who do not. One major challenge is that TNBC is a group of diseases that aren’t fully understood, which complicates the development of targeted therapies. Dr. Aparicio’s discovery of distinct subclasses of TNBC is a crucial advance in improving treatment approaches for this aggressive type of breast cancer.
Full Research Summary
Research area: Decoding the genomic makeup of triple negative breast cancers (TNBCs) to improve approaches to treatment.
Impact: TNBCs are hard to treat due to a lack of targeted therapies and the complex nature of the disease. Dr. Aparicio’s work decoding the genome sequences of TNBCs is now revealing vulnerabilities that could be used to design effective targeted therapies.
Current investigation: He and his team are using genome sequencing to investigate groupings of cellular mutations in patients that could one day be used to predict treatment responses.
What he’s learned so far: Dr. Aparicio has observed at least four distinct patterns of shuffling of the structure of chromosomes—patterns that may be predictive of sensitivity to drugs that directly target DNA.
What’s next: He and his team will test their theory that cancer-specific deficiencies in the ability to repair DNA could be a way of treating the subtypes of TNBC identified by these specific patterns in chromosomal structure shuffling. They also plan to test whether the patterns predict tendency to metastasize.
Dr. Samuel Aparicio (BM, BCh, PhD, FRCPath) is the Nan & Lorraine Robertson Chair in Breast Cancer Research, holds the Canada Research Chair in Molecular Oncology, and is the recipient of the 2014 Aubrey J Tingle Prize. He is also Head of the BCCA’s Department of Breast and Molecular Oncology, and a Professor in the Department of Pathology and Laboratory Medicine at UBC.HE graduated in medicine from Cambridge undertook clinical training in Oxford, subsequently in internal medicine and pathology. After doctoral work with Sydney Brenner in Cambridge he held a Wellcome Trust Career Development Fellowship at the Wellcome/CRUK Developmental Biology Institute. From 2000-2005 he was a senior investigator in the Department of Oncology, Cambridge. He was a co-leader of the international consortium that sequenced the genome of the pufferfish Fugu rubripes in 2002 and a visiting professor at the IMCB, Singapore.
Dr. Aparicio’s research program encompasses the fields of cancer genomics, laboratory genetic models, high throughput screens, small molecule chemical probes and translational breast cancer research. His most recent work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype. Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Contextual Genomics Ltd.
As a physician-scientist, the key philosophy of Dr. Aparicio’s program has been to provide a strong multidisciplinary environment for training of highly qualified personnel (HQP). His former trainees (career total 90) have gone on to success in academia: 1 institute director, 3 as PIs and others in medicine or in senior positions in industry or postgraduate education. All of his graduate students have been successful in securing national (CIHR, NSERC) or provincial (Michael Smith Foundation, CBCF BC/Yukon) competitive salary support and two of the four postdoctoral fellows are supported by independent peer reviewed salary awards from international (Australia), national (CBCF) and provincial (MSFHR) funding bodies.
Dr. Aparicio has published 172 papers in genomics and genetics of disease with >35,000 citations (H-index 77, i10 index 151). He has published in such high impact journals as: New England Journal of Medicine, Nature, Cell, Science, Nature Medicine, Nature Genetics, Nature Methods, Cell Stem Cell and Cell Metabolism.
BCRF Investigator Since
The Estée Lauder Companies' Canada Award